Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus]
Malfertheiner, P. ; O'Connor, H. J. ; Genta, R. M. ; Unge, P. ; Axon, A. T. R.
Oxford UK : Blackwell Science Ltd.
Published 2002
Oxford UK : Blackwell Science Ltd.
Published 2002
| ISSN: |
1365-2036
|
|---|---|
| Source: |
Blackwell Publishing Journal Backfiles 1879-2005
|
| Topics: |
Medicine
|
| Notes: |
Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease.The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori–gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks.Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser.Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy.
|
| Type of Medium: |
Electronic Resource
|
| URL: |
| _version_ | 1798290074998145025 |
|---|---|
| autor | Malfertheiner, P. O'Connor, H. J. Genta, R. M. Unge, P. Axon, A. T. R. |
| autorsonst | Unge, P. Axon, A. T. R. |
| book_url | http://dx.doi.org/10.1046/j.1365-2036.16.s3.1.x |
| datenlieferant | nat_lic_papers |
| hauptsatz | hsatz_simple |
| identnr | NLZ24220452X |
| insertion_date | 2012-04-27 |
| issn | 1365-2036 |
| journal_name | Alimentary pharmacology & therapeutics |
| materialart | 1 |
| notes | Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease.The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori–gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks.Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser.Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy. |
| package_name | Blackwell Publishing |
| publikationsjahr_anzeige | 2002 |
| publikationsjahr_facette | 2002 |
| publikationsjahr_intervall | 7999:2000-2004 |
| publikationsjahr_sort | 2002 |
| publikationsort | Oxford UK |
| publisher | Blackwell Science Ltd. |
| reference | 16 (2002), S. 0 |
| search_space | articles |
| shingle_author_1 | Malfertheiner, P. O'Connor, H. J. Genta, R. M. Unge, P. Axon, A. T. R. |
| shingle_author_2 | Malfertheiner, P. O'Connor, H. J. Genta, R. M. Unge, P. Axon, A. T. R. |
| shingle_author_3 | Malfertheiner, P. O'Connor, H. J. Genta, R. M. Unge, P. Axon, A. T. R. |
| shingle_author_4 | Malfertheiner, P. O'Connor, H. J. Genta, R. M. Unge, P. Axon, A. T. R. |
| shingle_catch_all_1 | Malfertheiner, P. O'Connor, H. J. Genta, R. M. Unge, P. Axon, A. T. R. Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus] Blackwell Science Ltd. Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease.The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori–gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks.Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser.Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy. 1365-2036 13652036 |
| shingle_catch_all_2 | Malfertheiner, P. O'Connor, H. J. Genta, R. M. Unge, P. Axon, A. T. R. Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus] Blackwell Science Ltd. Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease.The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori–gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks.Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser.Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy. 1365-2036 13652036 |
| shingle_catch_all_3 | Malfertheiner, P. O'Connor, H. J. Genta, R. M. Unge, P. Axon, A. T. R. Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus] Blackwell Science Ltd. Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease.The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori–gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks.Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser.Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy. 1365-2036 13652036 |
| shingle_catch_all_4 | Malfertheiner, P. O'Connor, H. J. Genta, R. M. Unge, P. Axon, A. T. R. Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus] Blackwell Science Ltd. Helicobacter pylori is a gastric pathogen that is a major cause of peptic ulcer disease, has a role in mucosa-associated lymphoid tissue (MALT) lymphoma and is associated with gastric cancer. Yet, in a large proportion of the human population, H. pylori infection has no apparent adverse clinical consequences. Furthermore, recent research suggests that H. pylori may even confer protection against gastroesophageal reflux disease.The conflicting evidence surrounding H. pylori infection was discussed at a sponsored symposium in Helsinki, introduced by Professor P. Malfertheiner, with papers presented by Dr H. J. O'Connor, Professor R. M. Genta, Dr P. Unge and Professor A. T. R. Axon. Emerging epidemiological and retrospective evidence suggests that the presence of H. pylori infection may provide some protection against gastroesophageal reflux disease, but there is other evidence that shows no benefit of H. pylori for the protection of the oesophagus. It was felt that prospective, multicentre studies are needed to explore the H. pylori–gastroesophageal disease relationship further, to avoid confusing potential benefits with known risks.Following the symposium, a discussion on the relative risks and benefits for H. pylori eradication was provided by Professor Axon and Professor Blaser.Eradication of H. pylori has been recommended in a series of management guidelines issued by consensus groups. However, accurate estimates of the relative risks and benefits of H. pylori infection in the general population, as well as in specific patient groups, is essential in order to develop a management strategy. 1365-2036 13652036 |
| shingle_title_1 | Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus] |
| shingle_title_2 | Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus] |
| shingle_title_3 | Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus] |
| shingle_title_4 | Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus] |
| sigel_instance_filter | dkfz geomar wilbert ipn albert |
| source_archive | Blackwell Publishing Journal Backfiles 1879-2005 |
| timestamp | 2024-05-06T08:10:57.517Z |
| titel | Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus] |
| titel_suche | Helicobacter pylori and clinical risks—focus on gastro-oesophageal reflux disease[This manus] |
| topic | WW-YZ |
| uid | nat_lic_papers_NLZ24220452X |